false false 2020-03-31 Q1 Q1 0001578845 0001620602 --12-31 --12-31 Large Accelerated Filer Non-accelerated Filer Yes Yes Yes Yes 1 1 0.017 0.235 0.019 P7Y 0.022 0.264 0.026 P1Y4M24D P1Y10M24D P3Y10M24D P3Y10M24D 2013 2014 2015 2016 2017 2010 2011 2012 2013 2010 2011 2012 2013 2014 2009 2010 2011 2012 2013 2014 0001578845 2020-01-01 2020-03-31 0001578845 agn:WarnerChilcottLimitedMember 2020-01-01 2020-03-31 0001578845 us-gaap:CommonStockMember 2020-01-01 2020-03-31 0001578845 agn:FloatingRateNotesDue2020Member 2020-01-01 2020-03-31 0001578845 agn:ZeroPointFiveZeroZeroPercentageNotesDueTwoThousandTwentyOneMember 2020-01-01 2020-03-31 0001578845 agn:OnePointFiveZeroZeroPercentageNotesDueTwoThousandTwentyThreeMember 2020-01-01 2020-03-31 0001578845 agn:OnePointTwoFiveZeroPercentageNotesDueTwoThousandTwentyFourMember 2020-01-01 2020-03-31 0001578845 agn:TwoPointSixTwoFivePercentageNotesDueTwoThousandTwentyEightMember 2020-01-01 2020-03-31 0001578845 agn:TwoPointOneTwoFivePercentageNotesDueTwoThousandTwentyNineMember 2020-01-01 2020-03-31 xbrli:shares 0001578845 2020-05-01 0001578845 agn:WarnerChilcottLimitedMember 2020-05-01 iso4217:USD 0001578845 2020-03-31 0001578845 2019-12-31 iso4217:USD xbrli:shares 0001578845 2019-01-01 2019-03-31 0001578845 2018-12-31 0001578845 2019-03-31 0001578845 us-gaap:CommonStockMember 2018-12-31 0001578845 us-gaap:AdditionalPaidInCapitalMember 2018-12-31 0001578845 us-gaap:RetainedEarningsMember 2018-12-31 0001578845 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2018-12-31 0001578845 us-gaap:NoncontrollingInterestMember 2018-12-31 0001578845 us-gaap:RetainedEarningsMember 2019-01-01 2019-03-31 0001578845 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2019-01-01 2019-03-31 0001578845 us-gaap:AdditionalPaidInCapitalMember 2019-01-01 2019-03-31 0001578845 us-gaap:CommonStockMember 2019-01-01 2019-03-31 0001578845 us-gaap:NoncontrollingInterestMember 2019-01-01 2019-03-31 0001578845 us-gaap:CommonStockMember 2019-03-31 0001578845 us-gaap:AdditionalPaidInCapitalMember 2019-03-31 0001578845 us-gaap:RetainedEarningsMember 2019-03-31 0001578845 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2019-03-31 0001578845 us-gaap:NoncontrollingInterestMember 2019-03-31 0001578845 us-gaap:CommonStockMember 2019-12-31 0001578845 us-gaap:AdditionalPaidInCapitalMember 2019-12-31 0001578845 us-gaap:RetainedEarningsMember 2019-12-31 0001578845 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2019-12-31 0001578845 us-gaap:NoncontrollingInterestMember 2019-12-31 0001578845 us-gaap:RetainedEarningsMember 2020-01-01 2020-03-31 0001578845 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2020-01-01 2020-03-31 0001578845 us-gaap:AdditionalPaidInCapitalMember 2020-01-01 2020-03-31 0001578845 us-gaap:CommonStockMember 2020-01-01 2020-03-31 0001578845 us-gaap:NoncontrollingInterestMember 2020-01-01 2020-03-31 0001578845 us-gaap:CommonStockMember 2020-03-31 0001578845 us-gaap:AdditionalPaidInCapitalMember 2020-03-31 0001578845 us-gaap:RetainedEarningsMember 2020-03-31 0001578845 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2020-03-31 0001578845 us-gaap:NoncontrollingInterestMember 2020-03-31 0001578845 agn:WarnerChilcottLimitedMember 2020-03-31 0001578845 agn:WarnerChilcottLimitedMember 2019-12-31 0001578845 agn:WarnerChilcottLimitedMember 2019-01-01 2019-03-31 0001578845 agn:WarnerChilcottLimitedMember 2018-12-31 0001578845 agn:WarnerChilcottLimitedMember 2019-03-31 0001578845 agn:WarnerChilcottLimitedMember us-gaap:MemberUnitsMember 2018-12-31 0001578845 agn:WarnerChilcottLimitedMember us-gaap:RetainedEarningsMember 2018-12-31 0001578845 agn:WarnerChilcottLimitedMember us-gaap:AccumulatedOtherComprehensiveIncomeMember 2018-12-31 0001578845 agn:WarnerChilcottLimitedMember us-gaap:NoncontrollingInterestMember 2018-12-31 0001578845 agn:WarnerChilcottLimitedMember us-gaap:RetainedEarningsMember 2019-01-01 2019-03-31 0001578845 agn:WarnerChilcottLimitedMember us-gaap:AccumulatedOtherComprehensiveIncomeMember 2019-01-01 2019-03-31 0001578845 agn:WarnerChilcottLimitedMember us-gaap:MemberUnitsMember 2019-01-01 2019-03-31 0001578845 agn:WarnerChilcottLimitedMember us-gaap:NoncontrollingInterestMember 2019-01-01 2019-03-31 0001578845 agn:WarnerChilcottLimitedMember us-gaap:MemberUnitsMember 2019-03-31 0001578845 agn:WarnerChilcottLimitedMember us-gaap:RetainedEarningsMember 2019-03-31 0001578845 agn:WarnerChilcottLimitedMember us-gaap:AccumulatedOtherComprehensiveIncomeMember 2019-03-31 0001578845 agn:WarnerChilcottLimitedMember us-gaap:NoncontrollingInterestMember 2019-03-31 0001578845 agn:WarnerChilcottLimitedMember us-gaap:MemberUnitsMember 2019-12-31 0001578845 agn:WarnerChilcottLimitedMember us-gaap:RetainedEarningsMember 2019-12-31 0001578845 agn:WarnerChilcottLimitedMember us-gaap:AccumulatedOtherComprehensiveIncomeMember 2019-12-31 0001578845 agn:WarnerChilcottLimitedMember us-gaap:NoncontrollingInterestMember 2019-12-31 0001578845 agn:WarnerChilcottLimitedMember us-gaap:RetainedEarningsMember 2020-01-01 2020-03-31 0001578845 agn:WarnerChilcottLimitedMember us-gaap:AccumulatedOtherComprehensiveIncomeMember 2020-01-01 2020-03-31 0001578845 agn:WarnerChilcottLimitedMember us-gaap:MemberUnitsMember 2020-01-01 2020-03-31 0001578845 agn:WarnerChilcottLimitedMember us-gaap:NoncontrollingInterestMember 2020-01-01 2020-03-31 0001578845 agn:WarnerChilcottLimitedMember us-gaap:MemberUnitsMember 2020-03-31 0001578845 agn:WarnerChilcottLimitedMember us-gaap:RetainedEarningsMember 2020-03-31 0001578845 agn:WarnerChilcottLimitedMember us-gaap:AccumulatedOtherComprehensiveIncomeMember 2020-03-31 0001578845 agn:WarnerChilcottLimitedMember us-gaap:NoncontrollingInterestMember 2020-03-31 agn:Country 0001578845 agn:AbbVieIncMember 2019-06-25 0001578845 agn:AbbVieIncMember 2019-06-24 2019-06-25 0001578845 agn:AbbVieIncMember 2019-10-25 0001578845 agn:AbbVieIncMember 2019-10-25 2019-10-25 0001578845 us-gaap:MaterialReconcilingItemsMember 2020-03-31 0001578845 us-gaap:MaterialReconcilingItemsMember 2019-12-31 0001578845 us-gaap:MaterialReconcilingItemsMember 2020-01-01 2020-03-31 0001578845 us-gaap:MaterialReconcilingItemsMember 2019-01-01 2019-03-31 0001578845 agn:ChargebacksMember 2019-12-31 0001578845 agn:RebatesMember 2019-12-31 0001578845 agn:ReturnsAndOtherAllowancesMember 2019-12-31 0001578845 agn:CashDiscountsMember 2019-12-31 0001578845 us-gaap:SalesReturnsAndAllowancesMember 2019-12-31 0001578845 agn:ChargebacksMember 2020-01-01 2020-03-31 0001578845 agn:RebatesMember 2020-01-01 2020-03-31 0001578845 agn:ReturnsAndOtherAllowancesMember 2020-01-01 2020-03-31 0001578845 agn:CashDiscountsMember 2020-01-01 2020-03-31 0001578845 us-gaap:SalesReturnsAndAllowancesMember 2020-01-01 2020-03-31 0001578845 agn:ChargebacksMember 2020-03-31 0001578845 agn:RebatesMember 2020-03-31 0001578845 agn:ReturnsAndOtherAllowancesMember 2020-03-31 0001578845 agn:CashDiscountsMember 2020-03-31 0001578845 us-gaap:SalesReturnsAndAllowancesMember 2020-03-31 0001578845 us-gaap:ProductMember 2020-01-01 2020-03-31 0001578845 us-gaap:ProductMember 2019-01-01 2019-03-31 xbrli:pure 0001578845 us-gaap:AccountingStandardsUpdate201409Member us-gaap:GeneralAndAdministrativeExpenseMember 2020-01-01 2020-03-31 0001578845 us-gaap:AccountingStandardsUpdate201409Member us-gaap:GeneralAndAdministrativeExpenseMember 2019-01-01 2019-03-31 0001578845 agn:StockAwardsMember 2020-01-01 2020-03-31 0001578845 agn:TwoThousandNineteenGrantsMember srt:MinimumMember 2020-01-01 2020-03-31 0001578845 agn:TwoThousandNineteenGrantsMember srt:MaximumMember 2020-01-01 2020-03-31 0001578845 agn:TwoThousandNineteenGrantsMember 2020-01-01 2020-03-31 0001578845 agn:EquityBasedCompensationAwardsMember 2020-01-01 2020-03-31 0001578845 agn:EquityBasedCompensationAwardsMember 2019-01-01 2019-03-31 0001578845 us-gaap:RestrictedStockMember 2019-12-31 0001578845 us-gaap:RestrictedStockMember 2020-01-01 2020-03-31 0001578845 us-gaap:RestrictedStockMember 2020-03-31 0001578845 us-gaap:RestrictedStockMember 2019-01-01 2019-12-31 0001578845 agn:NonQualifiedOptionsMember 2019-12-31 0001578845 agn:NonQualifiedOptionsMember 2020-01-01 2020-03-31 0001578845 agn:NonQualifiedOptionsMember 2020-03-31 0001578845 agn:NonQualifiedOptionsMember 2019-01-01 2019-12-31 agn:Segment 0001578845 us-gaap:OperatingSegmentsMember agn:USSpecializedTherapeuticsMember 2020-01-01 2020-03-31 0001578845 us-gaap:OperatingSegmentsMember agn:USGeneralMedicineMember 2020-01-01 2020-03-31 0001578845 us-gaap:OperatingSegmentsMember agn:InternationalMember 2020-01-01 2020-03-31 0001578845 us-gaap:OperatingSegmentsMember 2020-01-01 2020-03-31 0001578845 us-gaap:CorporateNonSegmentMember 2020-01-01 2020-03-31 0001578845 agn:USSpecializedTherapeuticsMember us-gaap:OperatingSegmentsMember 2019-01-01 2019-03-31 0001578845 agn:USGeneralMedicineMember us-gaap:OperatingSegmentsMember 2019-01-01 2019-03-31 0001578845 agn:InternationalMember us-gaap:OperatingSegmentsMember 2019-01-01 2019-03-31 0001578845 us-gaap:OperatingSegmentsMember 2019-01-01 2019-03-31 0001578845 us-gaap:CorporateNonSegmentMember 2019-01-01 2019-03-31 0001578845 srt:EuropeMember us-gaap:OperatingSegmentsMember agn:InternationalMember 2020-01-01 2020-03-31 0001578845 agn:AsiaPacificMiddleEastAndAfricaMember us-gaap:OperatingSegmentsMember agn:InternationalMember 2020-01-01 2020-03-31 0001578845 agn:LatinAmericaAndCanadaMember us-gaap:OperatingSegmentsMember agn:InternationalMember 2020-01-01 2020-03-31 0001578845 agn:OtherGeographicAreaMember us-gaap:OperatingSegmentsMember agn:InternationalMember 2020-01-01 2020-03-31 0001578845 srt:EuropeMember us-gaap:OperatingSegmentsMember agn:InternationalMember 2019-01-01 2019-03-31 0001578845 agn:AsiaPacificMiddleEastAndAfricaMember us-gaap:OperatingSegmentsMember agn:InternationalMember 2019-01-01 2019-03-31 0001578845 agn:LatinAmericaAndCanadaMember us-gaap:OperatingSegmentsMember agn:InternationalMember 2019-01-01 2019-03-31 0001578845 agn:OtherGeographicAreaMember us-gaap:OperatingSegmentsMember agn:InternationalMember 2019-01-01 2019-03-31 0001578845 agn:BotoxMember us-gaap:OperatingSegmentsMember agn:USSpecializedTherapeuticsMember 2020-01-01 2020-03-31 0001578845 agn:BotoxMember us-gaap:OperatingSegmentsMember agn:InternationalMember 2020-01-01 2020-03-31 0001578845 agn:BotoxMember us-gaap:OperatingSegmentsMember 2020-01-01 2020-03-31 0001578845 agn:RestasisMember us-gaap:OperatingSegmentsMember agn:USSpecializedTherapeuticsMember 2020-01-01 2020-03-31 0001578845 agn:RestasisMember us-gaap:OperatingSegmentsMember agn:InternationalMember 2020-01-01 2020-03-31 0001578845 agn:RestasisMember us-gaap:OperatingSegmentsMember 2020-01-01 2020-03-31 0001578845 agn:VraylarMember us-gaap:OperatingSegmentsMember agn:USGeneralMedicineMember 2020-01-01 2020-03-31 0001578845 agn:VraylarMember us-gaap:OperatingSegmentsMember 2020-01-01 2020-03-31 0001578845 agn:JuvedermCollectionMember us-gaap:OperatingSegmentsMember agn:USSpecializedTherapeuticsMember 2020-01-01 2020-03-31 0001578845 agn:JuvedermCollectionMember us-gaap:OperatingSegmentsMember agn:InternationalMember 2020-01-01 2020-03-31 0001578845 agn:JuvedermCollectionMember us-gaap:OperatingSegmentsMember 2020-01-01 2020-03-31 0001578845 agn:LinzessAndConstellaMember us-gaap:OperatingSegmentsMember agn:USGeneralMedicineMember 2020-01-01 2020-03-31 0001578845 agn:LinzessAndConstellaMember us-gaap:OperatingSegmentsMember agn:InternationalMember 2020-01-01 2020-03-31 0001578845 agn:LinzessAndConstellaMember us-gaap:OperatingSegmentsMember 2020-01-01 2020-03-31 0001578845 agn:LumiganAndGanfortMember us-gaap:OperatingSegmentsMember agn:USSpecializedTherapeuticsMember 2020-01-01 2020-03-31 0001578845 agn:LumiganAndGanfortMember us-gaap:OperatingSegmentsMember agn:InternationalMember 2020-01-01 2020-03-31 0001578845 agn:LumiganAndGanfortMember us-gaap:OperatingSegmentsMember 2020-01-01 2020-03-31 0001578845 agn:BystolicAndByvalsonMember us-gaap:OperatingSegmentsMember agn:USGeneralMedicineMember 2020-01-01 2020-03-31 0001578845 agn:BystolicAndByvalsonMember us-gaap:OperatingSegmentsMember agn:InternationalMember 2020-01-01 2020-03-31 0001578845 agn:BystolicAndByvalsonMember us-gaap:OperatingSegmentsMember 2020-01-01 2020-03-31 0001578845 agn:AlphaganAndCombiganMember us-gaap:OperatingSegmentsMember agn:USSpecializedTherapeuticsMember 2020-01-01 2020-03-31 0001578845 agn:AlphaganAndCombiganMember us-gaap:OperatingSegmentsMember agn:InternationalMember 2020-01-01 2020-03-31 0001578845 agn:AlphaganAndCombiganMember us-gaap:OperatingSegmentsMember 2020-01-01 2020-03-31 0001578845 agn:EyeDropsMember us-gaap:OperatingSegmentsMember agn:USSpecializedTherapeuticsMember 2020-01-01 2020-03-31 0001578845 agn:EyeDropsMember us-gaap:OperatingSegmentsMember agn:InternationalMember 2020-01-01 2020-03-31 0001578845 agn:EyeDropsMember us-gaap:OperatingSegmentsMember 2020-01-01 2020-03-31 0001578845 agn:LoLoestrinFeMember us-gaap:OperatingSegmentsMember agn:USGeneralMedicineMember 2020-01-01 2020-03-31 0001578845 agn:LoLoestrinFeMember us-gaap:OperatingSegmentsMember 2020-01-01 2020-03-31 0001578845 agn:AllodermMember us-gaap:OperatingSegmentsMember agn:USSpecializedTherapeuticsMember 2020-01-01 2020-03-31 0001578845 agn:AllodermMember us-gaap:OperatingSegmentsMember agn:InternationalMember 2020-01-01 2020-03-31 0001578845 agn:AllodermMember us-gaap:OperatingSegmentsMember 2020-01-01 2020-03-31 0001578845 agn:OzurdexMember us-gaap:OperatingSegmentsMember agn:USSpecializedTherapeuticsMember 2020-01-01 2020-03-31 0001578845 agn:OzurdexMember us-gaap:OperatingSegmentsMember agn:InternationalMember 2020-01-01 2020-03-31 0001578845 agn:OzurdexMember us-gaap:OperatingSegmentsMember 2020-01-01 2020-03-31 0001578845 agn:ViibrydFetzimaMember us-gaap:OperatingSegmentsMember agn:USGeneralMedicineMember 2020-01-01 2020-03-31 0001578845 agn:ViibrydFetzimaMember us-gaap:OperatingSegmentsMember agn:InternationalMember 2020-01-01 2020-03-31 0001578845 agn:ViibrydFetzimaMember us-gaap:OperatingSegmentsMember 2020-01-01 2020-03-31 0001578845 agn:ZenpepMember us-gaap:OperatingSegmentsMember agn:USGeneralMedicineMember 2020-01-01 2020-03-31 0001578845 agn:ZenpepMember us-gaap:OperatingSegmentsMember agn:InternationalMember 2020-01-01 2020-03-31 0001578845 agn:ZenpepMember us-gaap:OperatingSegmentsMember 2020-01-01 2020-03-31 0001578845 agn:ArmourThyroidMember us-gaap:OperatingSegmentsMember agn:USGeneralMedicineMember 2020-01-01 2020-03-31 0001578845 agn:ArmourThyroidMember us-gaap:OperatingSegmentsMember 2020-01-01 2020-03-31 0001578845 agn:BreastImplantsMember us-gaap:OperatingSegmentsMember agn:USSpecializedTherapeuticsMember 2020-01-01 2020-03-31 0001578845 agn:BreastImplantsMember us-gaap:OperatingSegmentsMember agn:InternationalMember 2020-01-01 2020-03-31 0001578845 agn:BreastImplantsMember us-gaap:OperatingSegmentsMember 2020-01-01 2020-03-31 0001578845 agn:SkinCareMember us-gaap:OperatingSegmentsMember agn:USSpecializedTherapeuticsMember 2020-01-01 2020-03-31 0001578845 agn:SkinCareMember us-gaap:OperatingSegmentsMember agn:InternationalMember 2020-01-01 2020-03-31 0001578845 agn:SkinCareMember us-gaap:OperatingSegmentsMember 2020-01-01 2020-03-31 0001578845 agn:ViberziMember us-gaap:OperatingSegmentsMember agn:USGeneralMedicineMember 2020-01-01 2020-03-31 0001578845 agn:ViberziMember us-gaap:OperatingSegmentsMember agn:InternationalMember 2020-01-01 2020-03-31 0001578845 agn:ViberziMember us-gaap:OperatingSegmentsMember 2020-01-01 2020-03-31 0001578845 agn:CoolsculptingSystemsAndAddOnApplicatorsMember us-gaap:OperatingSegmentsMember agn:USSpecializedTherapeuticsMember 2020-01-01 2020-03-31 0001578845 agn:CoolsculptingSystemsAndAddOnApplicatorsMember us-gaap:OperatingSegmentsMember agn:InternationalMember 2020-01-01 2020-03-31 0001578845 agn:CoolsculptingSystemsAndAddOnApplicatorsMember us-gaap:OperatingSegmentsMember 2020-01-01 2020-03-31 0001578845 agn:TeflaroMember us-gaap:OperatingSegmentsMember agn:USGeneralMedicineMember 2020-01-01 2020-03-31 0001578845 agn:TeflaroMember us-gaap:OperatingSegmentsMember agn:InternationalMember 2020-01-01 2020-03-31 0001578845 agn:TeflaroMember us-gaap:OperatingSegmentsMember 2020-01-01 2020-03-31 0001578845 agn:CoolsculptingConsumablesMember us-gaap:OperatingSegmentsMember agn:USSpecializedTherapeuticsMember 2020-01-01 2020-03-31 0001578845 agn:CoolsculptingConsumablesMember us-gaap:OperatingSegmentsMember agn:InternationalMember 2020-01-01 2020-03-31 0001578845 agn:CoolsculptingConsumablesMember us-gaap:OperatingSegmentsMember 2020-01-01 2020-03-31 0001578845 agn:SaphrisMember us-gaap:OperatingSegmentsMember agn:USGeneralMedicineMember 2020-01-01 2020-03-31 0001578845 agn:SaphrisMember us-gaap:OperatingSegmentsMember 2020-01-01 2020-03-31 0001578845 agn:DalvanceMember us-gaap:OperatingSegmentsMember agn:USGeneralMedicineMember 2020-01-01 2020-03-31 0001578845 agn:DalvanceMember us-gaap:OperatingSegmentsMember agn:InternationalMember 2020-01-01 2020-03-31 0001578845 agn:DalvanceMember us-gaap:OperatingSegmentsMember 2020-01-01 2020-03-31 0001578845 agn:LilettaMember us-gaap:OperatingSegmentsMember agn:USGeneralMedicineMember 2020-01-01 2020-03-31 0001578845 agn:LilettaMember us-gaap:OperatingSegmentsMember 2020-01-01 2020-03-31 0001578845 agn:CarafateAndSulcrateMember us-gaap:OperatingSegmentsMember agn:USGeneralMedicineMember 2020-01-01 2020-03-31 0001578845 agn:CarafateAndSulcrateMember us-gaap:OperatingSegmentsMember agn:InternationalMember 2020-01-01 2020-03-31 0001578845 agn:CarafateAndSulcrateMember us-gaap:OperatingSegmentsMember 2020-01-01 2020-03-31 0001578845 agn:SavellaMember us-gaap:OperatingSegmentsMember agn:USGeneralMedicineMember 2020-01-01 2020-03-31 0001578845 agn:SavellaMember us-gaap:OperatingSegmentsMember 2020-01-01 2020-03-31 0001578845 agn:NamzaricMember us-gaap:OperatingSegmentsMember agn:USGeneralMedicineMember 2020-01-01 2020-03-31 0001578845 agn:NamzaricMember us-gaap:OperatingSegmentsMember 2020-01-01 2020-03-31 0001578845 agn:AvycazMember us-gaap:OperatingSegmentsMember agn:USGeneralMedicineMember 2020-01-01 2020-03-31 0001578845 agn:AvycazMember us-gaap:OperatingSegmentsMember 2020-01-01 2020-03-31 0001578845 agn:CanasaAndSalofalkMember us-gaap:OperatingSegmentsMember agn:USGeneralMedicineMember 2020-01-01 2020-03-31 0001578845 agn:CanasaAndSalofalkMember us-gaap:OperatingSegmentsMember agn:InternationalMember 2020-01-01 2020-03-31 0001578845 agn:CanasaAndSalofalkMember us-gaap:OperatingSegmentsMember 2020-01-01 2020-03-31 0001578845 agn:UbrelvyMember us-gaap:OperatingSegmentsMember agn:USGeneralMedicineMember 2020-01-01 2020-03-31 0001578845 agn:UbrelvyMember us-gaap:OperatingSegmentsMember 2020-01-01 2020-03-31 0001578845 agn:DelzicolAndAsacolHDMember us-gaap:OperatingSegmentsMember agn:USGeneralMedicineMember 2020-01-01 2020-03-31 0001578845 agn:DelzicolAndAsacolHDMember us-gaap:OperatingSegmentsMember agn:InternationalMember 2020-01-01 2020-03-31 0001578845 agn:DelzicolAndAsacolHDMember us-gaap:OperatingSegmentsMember 2020-01-01 2020-03-31 0001578845 agn:KybellaAndBelkyraMember us-gaap:OperatingSegmentsMember agn:USSpecializedTherapeuticsMember 2020-01-01 2020-03-31 0001578845 agn:KybellaAndBelkyraMember us-gaap:OperatingSegmentsMember agn:InternationalMember 2020-01-01 2020-03-31 0001578845 agn:KybellaAndBelkyraMember us-gaap:OperatingSegmentsMember 2020-01-01 2020-03-31 0001578845 agn:AczoneMember us-gaap:OperatingSegmentsMember agn:USSpecializedTherapeuticsMember 2020-01-01 2020-03-31 0001578845 agn:AczoneMember us-gaap:OperatingSegmentsMember 2020-01-01 2020-03-31 0001578845 agn:NamendaMember us-gaap:OperatingSegmentsMember agn:USGeneralMedicineMember 2020-01-01 2020-03-31 0001578845 agn:NamendaMember us-gaap:OperatingSegmentsMember 2020-01-01 2020-03-31 0001578845 agn:RapafloMember us-gaap:OperatingSegmentsMember agn:USSpecializedTherapeuticsMember 2020-01-01 2020-03-31 0001578845 agn:RapafloMember us-gaap:OperatingSegmentsMember agn:InternationalMember 2020-01-01 2020-03-31 0001578845 agn:RapafloMember us-gaap:OperatingSegmentsMember 2020-01-01 2020-03-31 0001578845 agn:OtherMember us-gaap:OperatingSegmentsMember agn:USSpecializedTherapeuticsMember 2020-01-01 2020-03-31 0001578845 agn:OtherMember us-gaap:OperatingSegmentsMember agn:USGeneralMedicineMember 2020-01-01 2020-03-31 0001578845 agn:OtherMember us-gaap:OperatingSegmentsMember agn:InternationalMember 2020-01-01 2020-03-31 0001578845 agn:OtherMember us-gaap:OperatingSegmentsMember 2020-01-01 2020-03-31 0001578845 agn:USSpecializedTherapeuticsMember agn:BotoxMember us-gaap:OperatingSegmentsMember 2019-01-01 2019-03-31 0001578845 agn:InternationalMember agn:BotoxMember us-gaap:OperatingSegmentsMember 2019-01-01 2019-03-31 0001578845 agn:BotoxMember us-gaap:OperatingSegmentsMember 2019-01-01 2019-03-31 0001578845 agn:USSpecializedTherapeuticsMember agn:JuvedermCollectionMember us-gaap:OperatingSegmentsMember 2019-01-01 2019-03-31 0001578845 agn:InternationalMember agn:JuvedermCollectionMember us-gaap:OperatingSegmentsMember 2019-01-01 2019-03-31 0001578845 agn:JuvedermCollectionMember us-gaap:OperatingSegmentsMember 2019-01-01 2019-03-31 0001578845 agn:USSpecializedTherapeuticsMember agn:RestasisMember us-gaap:OperatingSegmentsMember 2019-01-01 2019-03-31 0001578845 agn:InternationalMember agn:RestasisMember us-gaap:OperatingSegmentsMember 2019-01-01 2019-03-31 0001578845 agn:RestasisMember us-gaap:OperatingSegmentsMember 2019-01-01 2019-03-31 0001578845 agn:USGeneralMedicineMember agn:LinzessAndConstellaMember us-gaap:OperatingSegmentsMember 2019-01-01 2019-03-31 0001578845 agn:InternationalMember agn:LinzessAndConstellaMember us-gaap:OperatingSegmentsMember 2019-01-01 2019-03-31 0001578845 agn:LinzessAndConstellaMember us-gaap:OperatingSegmentsMember 2019-01-01 2019-03-31 0001578845 agn:USGeneralMedicineMember agn:VraylarMember us-gaap:OperatingSegmentsMember 2019-01-01 2019-03-31 0001578845 agn:VraylarMember us-gaap:OperatingSegmentsMember 2019-01-01 2019-03-31 0001578845 agn:USSpecializedTherapeuticsMember agn:LumiganAndGanfortMember us-gaap:OperatingSegmentsMember 2019-01-01 2019-03-31 0001578845 agn:InternationalMember agn:LumiganAndGanfortMember us-gaap:OperatingSegmentsMember 2019-01-01 2019-03-31 0001578845 agn:LumiganAndGanfortMember us-gaap:OperatingSegmentsMember 2019-01-01 2019-03-31 0001578845 agn:USGeneralMedicineMember agn:BystolicAndByvalsonMember us-gaap:OperatingSegmentsMember 2019-01-01 2019-03-31 0001578845 agn:InternationalMember agn:BystolicAndByvalsonMember us-gaap:OperatingSegmentsMember 2019-01-01 2019-03-31 0001578845 agn:BystolicAndByvalsonMember us-gaap:OperatingSegmentsMember 2019-01-01 2019-03-31 0001578845 agn:USGeneralMedicineMember agn:LoLoestrinFeMember us-gaap:OperatingSegmentsMember 2019-01-01 2019-03-31 0001578845 agn:LoLoestrinFeMember us-gaap:OperatingSegmentsMember 2019-01-01 2019-03-31 0001578845 agn:USSpecializedTherapeuticsMember agn:AlphaganAndCombiganMember us-gaap:OperatingSegmentsMember 2019-01-01 2019-03-31 0001578845 agn:InternationalMember agn:AlphaganAndCombiganMember us-gaap:OperatingSegmentsMember 2019-01-01 2019-03-31 0001578845 agn:AlphaganAndCombiganMember us-gaap:OperatingSegmentsMember 2019-01-01 2019-03-31 0001578845 agn:USSpecializedTherapeuticsMember agn:EyeDropsMember us-gaap:OperatingSegmentsMember 2019-01-01 2019-03-31 0001578845 agn:InternationalMember agn:EyeDropsMember us-gaap:OperatingSegmentsMember 2019-01-01 2019-03-31 0001578845 agn:EyeDropsMember us-gaap:OperatingSegmentsMember 2019-01-01 2019-03-31 0001578845 agn:USSpecializedTherapeuticsMember agn:AllodermMember us-gaap:OperatingSegmentsMember 2019-01-01 2019-03-31 0001578845 agn:InternationalMember agn:AllodermMember us-gaap:OperatingSegmentsMember 2019-01-01 2019-03-31 0001578845 agn:AllodermMember us-gaap:OperatingSegmentsMember 2019-01-01 2019-03-31 0001578845 agn:USSpecializedTherapeuticsMember agn:OzurdexMember us-gaap:OperatingSegmentsMember 2019-01-01 2019-03-31 0001578845 agn:InternationalMember agn:OzurdexMember us-gaap:OperatingSegmentsMember 2019-01-01 2019-03-31 0001578845 agn:OzurdexMember us-gaap:OperatingSegmentsMember 2019-01-01 2019-03-31 0001578845 agn:USGeneralMedicineMember agn:ViibrydFetzimaMember us-gaap:OperatingSegmentsMember 2019-01-01 2019-03-31 0001578845 agn:InternationalMember agn:ViibrydFetzimaMember us-gaap:OperatingSegmentsMember 2019-01-01 2019-03-31 0001578845 agn:ViibrydFetzimaMember us-gaap:OperatingSegmentsMember 2019-01-01 2019-03-31 0001578845 agn:USSpecializedTherapeuticsMember agn:BreastImplantsMember us-gaap:OperatingSegmentsMember 2019-01-01 2019-03-31 0001578845 agn:InternationalMember agn:BreastImplantsMember us-gaap:OperatingSegmentsMember 2019-01-01 2019-03-31 0001578845 agn:BreastImplantsMember us-gaap:OperatingSegmentsMember 2019-01-01 2019-03-31 0001578845 agn:USSpecializedTherapeuticsMember agn:CoolsculptingConsumablesMember us-gaap:OperatingSegmentsMember 2019-01-01 2019-03-31 0001578845 agn:InternationalMember agn:CoolsculptingConsumablesMember us-gaap:OperatingSegmentsMember 2019-01-01 2019-03-31 0001578845 agn:CoolsculptingConsumablesMember us-gaap:OperatingSegmentsMember 2019-01-01 2019-03-31 0001578845 agn:USGeneralMedicineMember agn:ZenpepMember us-gaap:OperatingSegmentsMember 2019-01-01 2019-03-31 0001578845 agn:ZenpepMember us-gaap:OperatingSegmentsMember 2019-01-01 2019-03-31 0001578845 agn:USGeneralMedicineMember agn:CarafateAndSulcrateMember us-gaap:OperatingSegmentsMember 2019-01-01 2019-03-31 0001578845 agn:InternationalMember agn:CarafateAndSulcrateMember us-gaap:OperatingSegmentsMember 2019-01-01 2019-03-31 0001578845 agn:CarafateAndSulcrateMember us-gaap:OperatingSegmentsMember 2019-01-01 2019-03-31 0001578845 agn:USGeneralMedicineMember agn:ArmourThyroidMember us-gaap:OperatingSegmentsMember 2019-01-01 2019-03-31 0001578845 agn:ArmourThyroidMember us-gaap:OperatingSegmentsMember 2019-01-01 2019-03-31 0001578845 agn:USGeneralMedicineMember agn:ViberziMember us-gaap:OperatingSegmentsMember 2019-01-01 2019-03-31 0001578845 agn:InternationalMember agn:ViberziMember us-gaap:OperatingSegmentsMember 2019-01-01 2019-03-31 0001578845 agn:ViberziMember us-gaap:OperatingSegmentsMember 2019-01-01 2019-03-31 0001578845 agn:USSpecializedTherapeuticsMember agn:SkinCareMember us-gaap:OperatingSegmentsMember 2019-01-01 2019-03-31 0001578845 agn:InternationalMember agn:SkinCareMember us-gaap:OperatingSegmentsMember 2019-01-01 2019-03-31 0001578845 agn:SkinCareMember us-gaap:OperatingSegmentsMember 2019-01-01 2019-03-31 0001578845 agn:USGeneralMedicineMember agn:DelzicolAndAsacolHDMember us-gaap:OperatingSegmentsMember 2019-01-01 2019-03-31 0001578845 agn:InternationalMember agn:DelzicolAndAsacolHDMember us-gaap:OperatingSegmentsMember 2019-01-01 2019-03-31 0001578845 agn:DelzicolAndAsacolHDMember us-gaap:OperatingSegmentsMember 2019-01-01 2019-03-31 0001578845 agn:USGeneralMedicineMember agn:TeflaroMember us-gaap:OperatingSegmentsMember 2019-01-01 2019-03-31 0001578845 agn:InternationalMember agn:TeflaroMember us-gaap:OperatingSegmentsMember 2019-01-01 2019-03-31 0001578845 agn:TeflaroMember us-gaap:OperatingSegmentsMember 2019-01-01 2019-03-31 0001578845 agn:USGeneralMedicineMember agn:SaphrisMember us-gaap:OperatingSegmentsMember 2019-01-01 2019-03-31 0001578845 agn:SaphrisMember us-gaap:OperatingSegmentsMember 2019-01-01 2019-03-31 0001578845 agn:USGeneralMedicineMember agn:AvycazMember us-gaap:OperatingSegmentsMember 2019-01-01 2019-03-31 0001578845 agn:AvycazMember us-gaap:OperatingSegmentsMember 2019-01-01 2019-03-31 0001578845 agn:USSpecializedTherapeuticsMember agn:CoolsculptingSystemsAndAddOnApplicatorsMember us-gaap:OperatingSegmentsMember 2019-01-01 2019-03-31 0001578845 agn:InternationalMember agn:CoolsculptingSystemsAndAddOnApplicatorsMember us-gaap:OperatingSegmentsMember 2019-01-01 2019-03-31 0001578845 agn:CoolsculptingSystemsAndAddOnApplicatorsMember us-gaap:OperatingSegmentsMember 2019-01-01 2019-03-31 0001578845 agn:USGeneralMedicineMember agn:NamzaricMember us-gaap:OperatingSegmentsMember 2019-01-01 2019-03-31 0001578845 agn:NamzaricMember us-gaap:OperatingSegmentsMember 2019-01-01 2019-03-31 0001578845 agn:USGeneralMedicineMember agn:SavellaMember us-gaap:OperatingSegmentsMember 2019-01-01 2019-03-31 0001578845 agn:SavellaMember us-gaap:OperatingSegmentsMember 2019-01-01 2019-03-31 0001578845 agn:USGeneralMedicineMember agn:LilettaMember us-gaap:OperatingSegmentsMember 2019-01-01 2019-03-31 0001578845 agn:LilettaMember us-gaap:OperatingSegmentsMember 2019-01-01 2019-03-31 0001578845 agn:USGeneralMedicineMember agn:CanasaAndSalofalkMember us-gaap:OperatingSegmentsMember 2019-01-01 2019-03-31 0001578845 agn:InternationalMember agn:CanasaAndSalofalkMember us-gaap:OperatingSegmentsMember 2019-01-01 2019-03-31 0001578845 agn:CanasaAndSalofalkMember us-gaap:OperatingSegmentsMember 2019-01-01 2019-03-31 0001578845 agn:USSpecializedTherapeuticsMember agn:RapafloMember us-gaap:OperatingSegmentsMember 2019-01-01 2019-03-31 0001578845 agn:InternationalMember agn:RapafloMember us-gaap:OperatingSegmentsMember 2019-01-01 2019-03-31 0001578845 agn:RapafloMember us-gaap:OperatingSegmentsMember 2019-01-01 2019-03-31 0001578845 agn:USGeneralMedicineMember agn:DalvanceMember us-gaap:OperatingSegmentsMember 2019-01-01 2019-03-31 0001578845 agn:DalvanceMember us-gaap:OperatingSegmentsMember 2019-01-01 2019-03-31 0001578845 agn:USGeneralMedicineMember agn:NamendaMember us-gaap:OperatingSegmentsMember 2019-01-01 2019-03-31 0001578845 agn:NamendaMember us-gaap:OperatingSegmentsMember 2019-01-01 2019-03-31 0001578845 agn:USSpecializedTherapeuticsMember agn:KybellaAndBelkyraMember us-gaap:OperatingSegmentsMember 2019-01-01 2019-03-31 0001578845 agn:InternationalMember agn:KybellaAndBelkyraMember us-gaap:OperatingSegmentsMember 2019-01-01 2019-03-31 0001578845 agn:KybellaAndBelkyraMember us-gaap:OperatingSegmentsMember 2019-01-01 2019-03-31 0001578845 agn:USSpecializedTherapeuticsMember agn:AczoneMember us-gaap:OperatingSegmentsMember 2019-01-01 2019-03-31 0001578845 agn:AczoneMember us-gaap:OperatingSegmentsMember 2019-01-01 2019-03-31 0001578845 agn:USSpecializedTherapeuticsMember agn:OtherMember us-gaap:OperatingSegmentsMember 2019-01-01 2019-03-31 0001578845 agn:USGeneralMedicineMember agn:OtherMember us-gaap:OperatingSegmentsMember 2019-01-01 2019-03-31 0001578845 agn:InternationalMember agn:OtherMember us-gaap:OperatingSegmentsMember 2019-01-01 2019-03-31 0001578845 agn:OtherMember us-gaap:OperatingSegmentsMember 2019-01-01 2019-03-31 0001578845 agn:USSpecializedTherapeuticsMember 2019-12-31 0001578845 agn:USGeneralMedicineMember 2019-12-31 0001578845 agn:InternationalMember 2019-12-31 0001578845 agn:InternationalMember 2020-01-01 2020-03-31 0001578845 agn:USSpecializedTherapeuticsMember 2020-03-31 0001578845 agn:USGeneralMedicineMember 2020-03-31 0001578845 agn:InternationalMember 2020-03-31 0001578845 country:US srt:MinimumMember us-gaap:MeasurementInputDiscountRateMember 2020-01-01 2020-03-31 0001578845 agn:InternationalMember srt:MaximumMember us-gaap:MeasurementInputDiscountRateMember 2020-01-01 2020-03-31 0001578845 agn:USSpecializedTherapeuticsMember agn:USEyeCareReportingUnitMember 2020-03-31 0001578845 agn:USSpecializedTherapeuticsMember agn:USMedicalAestheticsReportingUnitMember 2020-03-31 0001578845 agn:ProductRightsAndOtherIntangiblesMember agn:CostBasisMember 2019-12-31 0001578845 us-gaap:TradeNamesMember agn:CostBasisMember 2019-12-31 0001578845 agn:CostBasisMember 2019-12-31 0001578845 agn:ProductRightsAndOtherIntangiblesMember agn:CostBasisMember 2020-01-01 2020-03-31 0001578845 us-gaap:TradeNamesMember agn:CostBasisMember 2020-01-01 2020-03-31 0001578845 agn:CostBasisMember 2020-01-01 2020-03-31 0001578845 agn:ProductRightsAndOtherIntangiblesMember agn:CostBasisMember 2020-03-31 0001578845 us-gaap:TradeNamesMember agn:CostBasisMember 2020-03-31 0001578845 agn:CostBasisMember 2020-03-31 0001578845 agn:IndefiniteInProcessResearchAndDevelopmentMember agn:CostBasisMember 2019-12-31 0001578845 agn:IndefiniteInProcessResearchAndDevelopmentMember agn:CostBasisMember 2020-01-01 2020-03-31 0001578845 agn:IndefiniteInProcessResearchAndDevelopmentMember agn:CostBasisMember 2020-03-31 0001578845 agn:ProductRightsAndOtherIntangiblesMember agn:AccumulatedAmortizationMember 2019-12-31 0001578845 us-gaap:TradeNamesMember agn:AccumulatedAmortizationMember 2019-12-31 0001578845 agn:AccumulatedAmortizationMember 2019-12-31 0001578845 agn:ProductRightsAndOtherIntangiblesMember agn:AccumulatedAmortizationMember 2020-01-01 2020-03-31 0001578845 us-gaap:TradeNamesMember agn:AccumulatedAmortizationMember 2020-01-01 2020-03-31 0001578845 agn:AccumulatedAmortizationMember 2020-01-01 2020-03-31 0001578845 agn:ProductRightsAndOtherIntangiblesMember agn:AccumulatedAmortizationMember 2020-03-31 0001578845 us-gaap:TradeNamesMember agn:AccumulatedAmortizationMember 2020-03-31 0001578845 agn:AccumulatedAmortizationMember 2020-03-31 0001578845 agn:KybellaMember agn:NonAnnualTestingMember 2020-01-01 2020-03-31 0001578845 agn:ProductRightsAndOtherRelatedIntangiblesMember 2020-03-31 0001578845 agn:FloatingRateNotesMember agn:SeniorNotesDueMarchTwelveTwoThousandTwentyMember 2019-12-31 0001578845 agn:FloatingRateNotesMember 2019-12-31 0001578845 agn:FixedRateNotesMember agn:ThreePointZeroZeroZeroPercentageSeniorNotesDueMarchTwelveTwoThousandTwentyMember 2019-12-31 0001578845 agn:FixedRateNotesMember agn:ThreePointThreeSevenFivePercentageSeniorNotesDueSeptemberFifteenTwoThousandTwentyMember 2020-03-31 0001578845 agn:FixedRateNotesMember agn:ThreePointThreeSevenFivePercentageSeniorNotesDueSeptemberFifteenTwoThousandTwentyMember 2019-12-31 0001578845 agn:FixedRateNotesMember agn:FourPointEightSevenFivePercentageSeniorNotesDueFebruaryFifteenTwoThousandTwentyOneMember 2020-03-31 0001578845 agn:FixedRateNotesMember agn:FourPointEightSevenFivePercentageSeniorNotesDueFebruaryFifteenTwoThousandTwentyOneMember 2019-12-31 0001578845 agn:FixedRateNotesMember agn:FivePointZeroZeroZeroPercentageSeniorNotesDueDecemberFifteenTwoThousandTwentyOneMember 2020-03-31 0001578845 agn:FixedRateNotesMember agn:FivePointZeroZeroZeroPercentageSeniorNotesDueDecemberFifteenTwoThousandTwentyOneMember 2019-12-31 0001578845 agn:FixedRateNotesMember agn:ThreePointFourFiveZeroPercentageSeniorNotesDueMarchFifteenTwoThousandTwentyTwoMember 2020-03-31 0001578845 agn:FixedRateNotesMember agn:ThreePointFourFiveZeroPercentageSeniorNotesDueMarchFifteenTwoThousandTwentyTwoMember 2019-12-31 0001578845 agn:FixedRateNotesMember agn:ThreePointTwoFiveZeroPercentageSeniorNotesDueOctoberOneTwoThousandTwentyTwoMember 2020-03-31 0001578845 agn:FixedRateNotesMember agn:ThreePointTwoFiveZeroPercentageSeniorNotesDueOctoberOneTwoThousandTwentyTwoMember 2019-12-31 0001578845 agn:FixedRateNotesMember agn:TwoPointEightZeroZeroPercentageSeniorNotesDueMarchFifteenTwoThousandTwentyThreeMember 2020-03-31 0001578845 agn:FixedRateNotesMember agn:TwoPointEightZeroZeroPercentageSeniorNotesDueMarchFifteenTwoThousandTwentyThreeMember 2019-12-31 0001578845 agn:FixedRateNotesMember agn:ThreePointEightFivePercentageSeniorNotesDueJuneFifteenTwoThousandTwentyFourMember 2020-03-31 0001578845 agn:FixedRateNotesMember agn:ThreePointEightFivePercentageSeniorNotesDueJuneFifteenTwoThousandTwentyFourMember 2019-12-31 0001578845 agn:FixedRateNotesMember agn:ThreePointEightZeroZeroPercentageSeniorNotesDueMarchFifteenTwoThousandTwentyFiveMember 2020-03-31 0001578845 agn:FixedRateNotesMember agn:ThreePointEightZeroZeroPercentageSeniorNotesDueMarchFifteenTwoThousandTwentyFiveMember 2019-12-31 0001578845 agn:FixedRateNotesMember agn:FourPointFiveFiveZeroPercentageSeniorNotesDueMarchFifteenTwoThousandThirtyFiveMember 2020-03-31 0001578845 agn:FixedRateNotesMember agn:FourPointFiveFiveZeroPercentageSeniorNotesDueMarchFifteenTwoThousandThirtyFiveMember 2019-12-31 0001578845 agn:FixedRateNotesMember agn:FourPointSixTwoFivePercentageSeniorNotesDueOctoberOneTwoThousandFortyTwoMember 2020-03-31 0001578845 agn:FixedRateNotesMember agn:FourPointSixTwoFivePercentageSeniorNotesDueOctoberOneTwoThousandFortyTwoMember 2019-12-31 0001578845 agn:FixedRateNotesMember agn:FourPointEightFivePercentageSeniorNotesDueJuneFifteenTwoThousandFortyFourMember 2020-03-31 0001578845 agn:FixedRateNotesMember agn:FourPointEightFivePercentageSeniorNotesDueJuneFifteenTwoThousandFortyFourMember 2019-12-31 0001578845 agn:FixedRateNotesMember agn:FourPointSevenFiveZeroPercentageSeniorNotesDueMarchFifteenTwoThousandFortyFiveMember 2020-03-31 0001578845 agn:FixedRateNotesMember agn:FourPointSevenFiveZeroPercentageSeniorNotesDueMarchFifteenTwoThousandFortyFiveMember 2019-12-31 0001578845 agn:FixedRateNotesMember 2020-03-31 0001578845 agn:FixedRateNotesMember 2019-12-31 0001578845 agn:EuroDenominatedNotesMember agn:SeniorNotesDueJuneOneTwoThousandNineteenMember 2020-03-31 0001578845 agn:EuroDenominatedNotesMember agn:SeniorNotesDueJuneOneTwoThousandNineteenMember 2019-12-31 0001578845 agn:EuroDenominatedNotesMember agn:ZeroPointFiveZeroZeroPercentageSeniorNotesDueJuneOneTwoThousandTwentyOneMember 2020-03-31 0001578845 agn:EuroDenominatedNotesMember agn:ZeroPointFiveZeroZeroPercentageSeniorNotesDueJuneOneTwoThousandTwentyOneMember 2019-12-31 0001578845 agn:EuroDenominatedNotesMember agn:OnePointFiveZeroZeroPercentageSeniorNotesDueNovemberFifteenTwoThousandTwentyThreeMember 2020-03-31 0001578845 agn:EuroDenominatedNotesMember agn:OnePointFiveZeroZeroPercentageSeniorNotesDueNovemberFifteenTwoThousandTwentyThreeMember 2019-12-31 0001578845 agn:EuroDenominatedNotesMember agn:OnePointTwoFiveZeroPercentageSeniorNotesDueJuneOneTwoThousandTwentyFourMember 2020-03-31 0001578845 agn:EuroDenominatedNotesMember agn:OnePointTwoFiveZeroPercentageSeniorNotesDueJuneOneTwoThousandTwentyFourMember 2019-12-31 0001578845 agn:EuroDenominatedNotesMember agn:TwoPointSixTwoFivePercentageSeniorNotesDueNovemberFifteenTwoThousandTwentyEightMember 2020-03-31 0001578845 agn:EuroDenominatedNotesMember agn:TwoPointSixTwoFivePercentageSeniorNotesDueNovemberFifteenTwoThousandTwentyEightMember 2019-12-31 0001578845 agn:EuroDenominatedNotesMember agn:TwoPointOneTwoFivePercentageSeniorNotesDueJuneOneTwoThousandTwentyNineMember 2020-03-31 0001578845 agn:EuroDenominatedNotesMember agn:TwoPointOneTwoFivePercentageSeniorNotesDueJuneOneTwoThousandTwentyNineMember 2019-12-31 0001578845 agn:EuroDenominatedNotesMember 2020-03-31 0001578845 agn:EuroDenominatedNotesMember 2019-12-31 0001578845 agn:OtherDebtMember 2020-03-31 0001578845 agn:OtherDebtMember 2019-12-31 0001578845 agn:FloatingRateNotesMember agn:SeniorNotesDueMarchTwelveTwoThousandTwentyMember 2020-01-01 2020-03-31 0001578845 agn:FixedRateNotesMember agn:ThreePointZeroZeroZeroPercentageSeniorNotesDueMarchTwelveTwoThousandTwentyMember 2020-01-01 2020-03-31 0001578845 agn:FixedRateNotesMember agn:ThreePointThreeSevenFivePercentageSeniorNotesDueSeptemberFifteenTwoThousandTwentyMember 2020-01-01 2020-03-31 0001578845 agn:FixedRateNotesMember agn:FourPointEightSevenFivePercentageSeniorNotesDueFebruaryFifteenTwoThousandTwentyOneMember 2020-01-01 2020-03-31 0001578845 agn:FixedRateNotesMember agn:FivePointZeroZeroZeroPercentageSeniorNotesDueDecemberFifteenTwoThousandTwentyOneMember 2020-01-01 2020-03-31 0001578845 agn:FixedRateNotesMember agn:ThreePointFourFiveZeroPercentageSeniorNotesDueMarchFifteenTwoThousandTwentyTwoMember 2020-01-01 2020-03-31 0001578845 agn:FixedRateNotesMember agn:ThreePointTwoFiveZeroPercentageSeniorNotesDueOctoberOneTwoThousandTwentyTwoMember 2020-01-01 2020-03-31 0001578845 agn:FixedRateNotesMember agn:TwoPointEightZeroZeroPercentageSeniorNotesDueMarchFifteenTwoThousandTwentyThreeMember 2020-01-01 2020-03-31 0001578845 agn:FixedRateNotesMember agn:ThreePointEightFivePercentageSeniorNotesDueJuneFifteenTwoThousandTwentyFourMember 2020-01-01 2020-03-31 0001578845 agn:FixedRateNotesMember agn:ThreePointEightZeroZeroPercentageSeniorNotesDueMarchFifteenTwoThousandTwentyFiveMember 2020-01-01 2020-03-31 0001578845 agn:FixedRateNotesMember agn:FourPointFiveFiveZeroPercentageSeniorNotesDueMarchFifteenTwoThousandThirtyFiveMember 2020-01-01 2020-03-31 0001578845 agn:FixedRateNotesMember agn:FourPointSixTwoFivePercentageSeniorNotesDueOctoberOneTwoThousandFortyTwoMember 2020-01-01 2020-03-31 0001578845 agn:FixedRateNotesMember agn:FourPointEightFivePercentageSeniorNotesDueJuneFifteenTwoThousandFortyFourMember 2020-01-01 2020-03-31 0001578845 agn:FixedRateNotesMember agn:FourPointSevenFiveZeroPercentageSeniorNotesDueMarchFifteenTwoThousandFortyFiveMember 2020-01-01 2020-03-31 0001578845 agn:EuroDenominatedNotesMember agn:SeniorNotesDueJuneOneTwoThousandNineteenMember 2020-01-01 2020-03-31 0001578845 agn:EuroDenominatedNotesMember agn:ZeroPointFiveZeroZeroPercentageSeniorNotesDueJuneOneTwoThousandTwentyOneMember 2020-01-01 2020-03-31 0001578845 agn:EuroDenominatedNotesMember agn:OnePointFiveZeroZeroPercentageSeniorNotesDueNovemberFifteenTwoThousandTwentyThreeMember 2020-01-01 2020-03-31 0001578845 agn:EuroDenominatedNotesMember agn:OnePointTwoFiveZeroPercentageSeniorNotesDueJuneOneTwoThousandTwentyFourMember 2020-01-01 2020-03-31 0001578845 agn:EuroDenominatedNotesMember agn:TwoPointSixTwoFivePercentageSeniorNotesDueNovemberFifteenTwoThousandTwentyEightMember 2020-01-01 2020-03-31 0001578845 agn:EuroDenominatedNotesMember agn:TwoPointOneTwoFivePercentageSeniorNotesDueJuneOneTwoThousandTwentyNineMember 2020-01-01 2020-03-31 0001578845 agn:SeniorNotesDueNovemberFifteenTwoThousandTwentyMember agn:FloatingRateNotesMember 2020-01-01 2020-03-31 0001578845 agn:ThreePointZeroZeroZeroPercentageSeniorNotesDueMarchTwelveTwoThousandTwentyMember agn:FixedRateNotesMember 2020-03-31 0001578845 agn:EuroDenominatedNotesMember agn:SeniorNotesDueNovemberFifteenTwoThousandTwentyMember 2020-01-01 2020-03-31 0001578845 agn:FloatingRateNotesMember 2020-01-01 2020-03-31 0001578845 agn:FixedRateNotesMember 2020-01-01 2020-03-31 0001578845 us-gaap:DomesticCountryMember 2019-01-01 2019-03-31 0001578845 agn:AllerganWCHoldingIncMember us-gaap:InternalRevenueServiceIRSMember 2019-01-01 2019-03-31 0001578845 agn:AllerganPharmaIncSubsidiariesMember us-gaap:InternalRevenueServiceIRSMember 2019-01-01 2019-03-31 0001578845 agn:WarnerChilcottCorporationMember us-gaap:InternalRevenueServiceIRSMember 2019-01-01 2019-03-31 0001578845 agn:ForestLaboratoriesIncMember us-gaap:InternalRevenueServiceIRSMember 2019-01-01 2019-03-31 0001578845 agn:AllerganIncMember us-gaap:InternalRevenueServiceIRSMember 2019-01-01 2019-03-31 0001578845 us-gaap:CashFlowHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember us-gaap:InterestRateSwapMember 2019-01-31 0001578845 us-gaap:CashFlowHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember us-gaap:InterestRateSwapMember 2019-01-01 2019-01-31 0001578845 us-gaap:CashFlowHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember us-gaap:InterestRateSwapMember 2020-01-01 2020-03-31 0001578845 us-gaap:DesignatedAsHedgingInstrumentMember 2020-03-31 0001578845 us-gaap:DesignatedAsHedgingInstrumentMember 2019-12-31 0001578845 us-gaap:DesignatedAsHedgingInstrumentMember 2019-01-01 2019-03-31 0001578845 us-gaap:DesignatedAsHedgingInstrumentMember 2020-01-01 2020-03-31 0001578845 us-gaap:CashEquivalentsMember us-gaap:FairValueMeasurementsRecurringMember 2020-03-31 0001578845 us-gaap:CashEquivalentsMember us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2020-03-31 0001578845 us-gaap:FairValueMeasurementsRecurringMember 2020-03-31 0001578845 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2020-03-31 0001578845 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2020-03-31 0001578845 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2020-03-31 0001578845 srt:MaximumMember 2020-01-01 2020-03-31 0001578845 srt:MaximumMember 2019-01-01 2019-12-31 0001578845 us-gaap:CashEquivalentsMember us-gaap:FairValueMeasurementsRecurringMember 2019-12-31 0001578845 us-gaap:CashEquivalentsMember us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2019-12-31 0001578845 us-gaap:FairValueMeasurementsRecurringMember 2019-12-31 0001578845 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2019-12-31 0001578845 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2019-12-31 0001578845 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2019-12-31 0001578845 us-gaap:CostOfSalesMember 2020-01-01 2020-03-31 0001578845 us-gaap:CostOfSalesMember 2019-01-01 2019-03-31 0001578845 us-gaap:ResearchAndDevelopmentExpenseMember 2020-01-01 2020-03-31 0001578845 us-gaap:ResearchAndDevelopmentExpenseMember 2019-01-01 2019-03-31 0001578845 agn:ContingentConsiderationObligationMember 2019-12-31 0001578845 agn:ContingentConsiderationObligationMember 2020-01-01 2020-03-31 0001578845 agn:ContingentConsiderationObligationMember 2020-03-31 0001578845 agn:ContingentConsiderationObligationMember 2018-12-31 0001578845 agn:ContingentConsiderationObligationMember 2019-01-01 2019-03-31 0001578845 agn:ContingentConsiderationObligationMember 2019-03-31 0001578845 agn:TobiraTherapeuticsIncMember agn:ContingentConsiderationObligationMember 2019-12-31 0001578845 agn:MedicinesThreeSixZeroMember agn:ContingentConsiderationObligationMember 2019-12-31 0001578845 agn:AqueSysAcquisitionMember agn:ContingentConsiderationObligationMember 2019-12-31 0001578845 agn:OculeveAcquisitionMember agn:ContingentConsiderationObligationMember 2019-12-31 0001578845 agn:ForSightMember agn:ContingentConsiderationObligationMember 2019-12-31 0001578845 agn:ForestLaboratoriesIncMember agn:ContingentConsiderationObligationMember 2019-12-31 0001578845 agn:OtherAcquisitionMember agn:ContingentConsiderationObligationMember 2019-12-31 0001578845 agn:TobiraTherapeuticsIncMember agn:ContingentConsiderationObligationMember 2020-01-01 2020-03-31 0001578845 agn:MedicinesThreeSixZeroMember agn:ContingentConsiderationObligationMember 2020-01-01 2020-03-31 0001578845 agn:OculeveAcquisitionMember agn:ContingentConsiderationObligationMember 2020-01-01 2020-03-31 0001578845 agn:ForestLaboratoriesIncMember agn:ContingentConsiderationObligationMember 2020-01-01 2020-03-31 0001578845 agn:TobiraTherapeuticsIncMember agn:ContingentConsiderationObligationMember 2020-03-31 0001578845 agn:MedicinesThreeSixZeroMember agn:ContingentConsiderationObligationMember 2020-03-31 0001578845 agn:AqueSysAcquisitionMember agn:ContingentConsiderationObligationMember 2020-03-31 0001578845 agn:OculeveAcquisitionMember agn:ContingentConsiderationObligationMember 2020-03-31 0001578845 agn:ForSightMember agn:ContingentConsiderationObligationMember 2020-03-31 0001578845 agn:ForestLaboratoriesIncMember agn:ContingentConsiderationObligationMember 2020-03-31 0001578845 agn:OtherAcquisitionMember agn:ContingentConsiderationObligationMember 2020-03-31 0001578845 agn:BystolicMember agn:AjantaMember 2020-01-01 2020-03-31 0001578845 agn:SandozIncorporationMember us-gaap:PendingLitigationMember 2018-08-01 2018-08-01 0001578845 agn:PrinstonMember 2020-01-01 2020-03-31 0001578845 agn:SunAndSunCertainAffiliatesMember 2020-01-01 2020-03-31 0001578845 agn:AurobindoMember 2020-01-01 2020-03-31 0001578845 agn:MylanMember 2020-01-01 2020-03-31 0001578845 agn:KBCMediaRelationsLimitedLiabilityCompanyMember agn:JuvedermMember 2020-01-01 2020-03-31 iso4217:EUR 0001578845 agn:DermavitaLimitedPartnershipMember srt:MinimumMember 2020-01-01 2020-03-31 agn:Trademark 0001578845 agn:DermavitaLimitedPartnershipMember srt:MinimumMember 2020-03-31 0001578845 agn:LoestrinTwentyFourLitigationMember 2020-03-31 0001578845 agn:NamendaLitigationMember 2020-01-01 2020-03-31 agn:Claim 0001578845 agn:WarnerChilcottMarketingPracticesMember agn:WarnerChilcottLimitedMember 2020-01-01 2020-03-31 agn:Plaintiff 0001578845 agn:GenericDrugPricingSecuritiesLitigationMember stpr:NJ 2020-01-01 2020-03-31 agn:Defendant 0001578845 agn:PrescriptionDrugAbuseLitigationMember us-gaap:PendingLitigationMember 2020-03-31 agn:Cases 0001578845 agn:ProductLiabilityLitigationMember srt:MinimumMember 2020-01-01 2020-03-31 0001578845 agn:ProductLiabilityLitigationMember us-gaap:PendingLitigationMember country:CA 2020-03-31 0001578845 agn:ProductLiabilityLitigationMember us-gaap:PendingLitigationMember 2020-01-01 2020-03-31 0001578845 agn:ProductLiabilityLitigationMember agn:BreastImplantLitigationMember country:CA srt:MinimumMember 2020-01-01 2020-03-31 0001578845 agn:ProductLiabilityLitigationMember srt:MinimumMember agn:CelexaLexaproLitigationMember 2020-01-01 2020-03-31 0001578845 agn:ProductLiabilityLitigationMember srt:MinimumMember agn:RepliFormLitigationMember 2020-01-01 2020-03-31 0001578845 agn:ProductLiabilityLitigationMember agn:RepliFormLitigationMember 2020-03-31 agn:Product 0001578845 agn:BotoxMember 2015-12-27 2015-12-28 agn:Patent 0001578845 agn:SaintRegisMohawkTribeMember agn:RestasisMember 2015-12-28 0001578845 agn:WarnerChilcottLimitedParentGuarantorMember 2020-03-31 0001578845 agn:AllerganCapitalSarlMember 2020-03-31 0001578845 agn:AllerganFundingScsMember 2020-03-31 0001578845 agn:NonGuarantorsMember 2020-03-31 0001578845 agn:AllerganFinanceLimitedLiabilityCompanyMember 2020-03-31 0001578845 srt:ConsolidationEliminationsMember 2020-03-31 0001578845 agn:WarnerChilcottLimitedParentGuarantorMember 2019-12-31 0001578845 agn:AllerganCapitalSarlMember 2019-12-31 0001578845 agn:AllerganFundingScsMember 2019-12-31 0001578845 agn:NonGuarantorsMember 2019-12-31 0001578845 agn:AllerganFinanceLimitedLiabilityCompanyMember 2019-12-31 0001578845 srt:ConsolidationEliminationsMember 2019-12-31 0001578845 agn:NonGuarantorsMember 2020-01-01 2020-03-31 0001578845 agn:AllerganCapitalSarlMember 2020-01-01 2020-03-31 0001578845 agn:AllerganFundingScsMember 2020-01-01 2020-03-31 0001578845 agn:AllerganFinanceLimitedLiabilityCompanyMember 2020-01-01 2020-03-31 0001578845 agn:WarnerChilcottLimitedParentGuarantorMember 2020-01-01 2020-03-31 0001578845 srt:ConsolidationEliminationsMember 2020-01-01 2020-03-31 0001578845 agn:NonGuarantorsMember 2019-01-01 2019-03-31 0001578845 agn:AllerganCapitalSarlMember 2019-01-01 2019-03-31 0001578845 agn:AllerganFundingScsMember 2019-01-01 2019-03-31 0001578845 agn:AllerganFinanceLimitedLiabilityCompanyMember 2019-01-01 2019-03-31 0001578845 agn:WarnerChilcottLimitedParentGuarantorMember 2019-01-01 2019-03-31 0001578845 srt:ConsolidationEliminationsMember 2019-01-01 2019-03-31 0001578845 agn:WarnerChilcottLimitedParentGuarantorMember 2018-12-31 0001578845 agn:AllerganCapitalSarlMember 2018-12-31 0001578845 agn:AllerganFundingScsMember 2018-12-31 0001578845 agn:NonGuarantorsMember 2018-12-31 0001578845 agn:WarnerChilcottLimitedParentGuarantorMember 2019-03-31 0001578845 agn:AllerganCapitalSarlMember 2019-03-31 0001578845 agn:AllerganFundingScsMember 2019-03-31 0001578845 agn:NonGuarantorsMember 2019-03-31

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

Form 10-Q

☒	QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended March 31, 2020

☐	TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from to

Commission File Number	Exact name of registrant as specified in its charter, principal office and address and telephone number	State of incorporation or organization	I.R.S. Employer Identification No.
001-36867	Allergan plc Clonshaugh Business and Technology Park Coolock, Dublin, D17 E400, Ireland (862) 261-7000	Ireland	98-1114402

001-36887	Warner Chilcott Limited	Bermuda	98-0496358
	Victoria Place, 5^th Floor
	Hamilton HM 10
	Bermuda
	(441) 295-2244

Title of Each Class	Trading Symbol	Name of Each Exchange on Which Registered
Allergan plc Ordinary Shares, $0.0001 par value	AGN	New York Stock Exchange
Floating rate notes due 2020	AGN20A	New York Stock Exchange
0.500% notes due 2021	AGN21	New York Stock Exchange
1.500% notes due 2023	AGN 23A	New York Stock Exchange
1.250% notes due 2024	AGN 24A	New York Stock Exchange
2.625% notes due 2028	AGN28	New York Stock Exchange
2.125% notes due 2029	AGN29	New York Stock Exchange

Securities registered pursuant to Section 12(b) of the Act:

Title of Each Class	Trading Symbol	Name of Each Exchange on Which Registered
Allergan plc Ordinary Shares, $0.0001 par value	AGN	New York Stock Exchange

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days:

Allergan plc		YES ☒		NO ☐
Warner Chilcott Limited		YES ☒		NO ☐

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§ 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).

Allergan plc		YES ☒		NO ☐
Warner Chilcott Limited		YES ☒		NO ☐

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

Allergan plc	Large accelerated filer	☒	Accelerated filer	☐
	Non-accelerated filer	☐	Smaller reporting company	☐
	Emerging growth company	☐

Warner Chilcott Limited	Large accelerated filer	☐	Accelerated filer	☐
	Non-accelerated filer	☒	Smaller reporting company	☐
	Emerging growth company	☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Act).

Allergan plc		YES ☐		NO ☒
Warner Chilcott Limited		YES ☐		NO ☒

Number of shares of Allergan plc’s Ordinary Shares outstanding on May 1, 2020: 329,805,791. There is no trading market for securities of Warner Chilcott Limited, all of which are indirectly wholly owned by Allergan plc.

This Quarterly Report on Form 10-Q is a combined report being filed separately by two different registrants: Allergan plc and Warner Chilcott Limited. Warner Chilcott Limited is an indirect wholly-owned subsidiary of Allergan plc. The information in this Quarterly Report on Form 10-Q is equally applicable to Allergan plc and Warner Chilcott Limited, except where otherwise indicated. Warner Chilcott Limited meets the conditions set forth in General Instruction H(1)(a) and (b) of Form 10-Q and, to the extent applicable, is therefore filing this form with a reduced disclosure format.

TABLE OF CONTENTS

FORM 10-Q FOR THE QUARTERLY PERIOD ENDED MARCH 31, 2020

		PAGE
PART I. FINANCIAL INFORMATION
Item 1.	Consolidated Financial Statements (unaudited)	3
	Consolidated Balance Sheets of Allergan plc as of March 31, 2020 and December 31, 2019	3
	Consolidated Statements of Operations of Allergan plc for the three months ended March 31, 2020 and March 31, 2019	4
	Consolidated Statements of Comprehensive Income / (Loss) of Allergan plc for the three months ended March 31, 2020 and March 31, 2019	5
	Consolidated Statements of Cash Flows of Allergan plc for the three months ended March 31, 2020 and March 31, 2019	6
	Consolidated Statements of Equity of Allergan plc for the three months ended March 31, 2020 and March 31, 2019	7
	Consolidated Balance Sheets of Warner Chilcott Limited as of March 31, 2020 and December 31, 2019	8
	Consolidated Statements of Operations of Warner Chilcott Limited for the three months ended March 31, 2020 and March 31, 2019	9
	Consolidated Statements of Comprehensive Income / (Loss) of Warner Chilcott Limited for the three months ended March 31, 2020 and March 31, 2019	10
	Consolidated Statements of Cash Flows of Warner Chilcott Limited for the three months ended March 31, 2020 and March 31, 2019	11
	Consolidated Statements of Equity of Warner Chilcott Limited for the three months ended March 31, 2020 and March 31, 2019	12
	Notes to the Consolidated Financial Statements	13
Item 2.	Management’s Discussion and Analysis of Financial Condition and Results of Operations	54
Item 3.	Quantitative and Qualitative Disclosures About Market Risk	70
Item 4.	Controls and Procedures	71
PART II. OTHER INFORMATION		73
Item 1.	Legal Proceedings	73
Item 1A.	Risk Factors	73
Item 2.	Unregistered Sales of Equity Securities and Use of Proceeds	74
Item 6.	Exhibits	75
	Signatures	76

PART I. FINANCIAL INFORMATION

ITEM 1.

CONSOLIDATED FINANCIAL STATEMENTS

ALLERGAN PLC

CONSOLIDATED BALANCE SHEETS

(Unaudited; in millions, except par value)

	March 31,		December 31,
	2020		2019
ASSETS
Current assets:
Cash and cash equivalents	$	999.5	$	2,503.3
Marketable securities		1,618.8		3,411.6
Accounts receivable, net of allowances for doubtful accounts and credit losses of $144.8 and $110.8		2,800.6		3,192.3
Inventories		1,199.9		1,133.1
Prepaid expenses and other current assets		855.3		886.4
Total current assets		7,474.1		11,126.7
Property, plant and equipment, net		1,915.4		1,926.5
Right of use asset - operating leases		481.0		490.4
Investments and other assets		430.7		408.0
Non current assets held for sale		31.7		31.7
Deferred tax assets		597.9		576.9
Product rights and other intangibles		36,266.2		37,890.6
Goodwill		41,229.2		42,248.3
Total assets	$	88,426.2	$	94,699.1
LIABILITIES AND EQUITY
Current liabilities:
Accounts payable and accrued expenses	$	5,289.5	$	6,348.7
Income taxes payable		73.4		65.1
Current portion of long-term debt		1,950.7		4,532.5
Current portion of lease liability - operating		119.8		124.4
Total current liabilities		7,433.4		11,070.7
Long-term debt		17,599.0		18,116.5
Lease liability - operating		438.3		446.1
Other long-term liabilities		787.4		800.9
Other taxes payable		1,690.4		1,704.8
Deferred tax liabilities		2,456.2		4,363.7
Total liabilities		30,404.7		36,502.7
Commitments and contingencies (Refer to Note 15)
Equity:
Ordinary shares; $0.0001 par value per share; 1,000.0 million shares authorized, 329.7 million and 328.6 million shares issued and outstanding, respectively	$	-	$	-
Additional paid-in capital		56,036.2		55,974.9
Retained earnings		882.5		991.5
Accumulated other comprehensive income		1,079.0		1,207.2
Total shareholders’ equity		57,997.7		58,173.6
Noncontrolling interest		23.8		22.8
Total equity		58,021.5		58,196.4
Total liabilities and equity	$	88,426.2	$	94,699.1

See accompanying Notes to the Consolidated Financial Statements.

ALLERGAN PLC

CONSOLIDATED STATEMENTS OF OPERATIONS

(Unaudited; in millions, except per share amounts)

	Three Months Ended March 31,
	2020			2019
Net revenues	$	3,604.4		$	3,597.1
Operating expenses:
Cost of sales (excludes amortization and impairment of acquired intangibles including product rights)		623.1			497.8
Research and development		430.0			435.0
Selling and marketing		972.1			804.0
General and administrative		401.3			308.3
Amortization		1,416.4			1,399.4
Goodwill impairments		913.0			2,467.0
Asset sales and impairments, net		148.1			(5.2	)
Total operating expenses		4,904.0			5,906.3
Operating (loss) / income		(1,299.6	)		(2,309.2	)

Interest income		21.2			21.3
Interest (expense)		(184.5	)		(201.8	)
Other income / (expense), net		(24.9	)		13.8
Total other (expense), net		(188.2	)		(166.7	)
(Loss) before income taxes and noncontrolling interest		(1,487.8	)		(2,475.9	)
(Benefit) for income taxes		(1,866.8	)		(68.6	)
Net income / (loss)		379.0			(2,407.3	)
(Income) attributable to noncontrolling interest		(1.0	)		(0.7	)
Net Income / (loss) attributable to shareholders	$	378.0		$	(2,408.0	)

Income / (Loss) per share attributable to shareholders
Basic	$	1.15		$	(7.25	)
Diluted	$	1.14		$	(7.25	)

Weighted average shares outstanding:
Basic		329.1			332.0
Diluted		331.9			332.0

See accompanying Notes to the Consolidated Financial Statements.

ALLERGAN PLC

CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME / (LOSS)

(Unaudited; in millions)

	Three Months Ended March 31,
	2020			2019
Net income / (loss)	$	379.0		$	(2,407.3	)
Other comprehensive (loss) / income
Foreign currency translation (losses)		(127.2	)		(127.8	)
Unrealized (losses), net of tax		(1.0	)		(1.0	)
Total other comprehensive (loss), net of tax		(128.2	)		(128.8	)
Comprehensive income / (loss)		250.8			(2,536.1	)
Comprehensive (income) attributable to noncontrolling interest		(1.0	)		(0.7	)
Comprehensive income / (loss) attributable to ordinary shareholders	$	249.8		$	(2,536.8	)

See accompanying Notes to the Consolidated Financial Statements.

ALLERGAN PLC

CONSOLIDATED STATEMENTS OF CASH FLOWS

(Unaudited; in millions)

	Three Months Ended March 31,
	2020			2019
Cash Flows From Operating Activities:
Net income / (loss)	$	379.0		$	(2,407.3	)
Reconciliation to net cash provided by operating activities:
Depreciation		56.8			47.5
Amortization		1,416.4			1,399.4
Provision for inventory reserve		28.4			18.8
Share-based compensation		51.6			52.3
Deferred income tax benefit		(1,931.1	)		(229.7	)
Goodwill impairments		913.0			2,467.0
(Gain) / loss on asset sales and impairments, net		148.1			(5.2	)
Non-cash extinguishment of debt		-			0.3
Amortization of deferred financing costs		4.1			4.6
Non-cash lease expense		35.9			30.1
Contingent consideration adjustments, including accretion		26.6			18.7
Other, net		65.2			(10.3	)
Changes in assets and liabilities (net of effects of acquisitions):
Decrease / (increase) in accounts receivable, net		330.2			132.4
Decrease / (increase) in inventories		(126.3	)		(128.3	)
Decrease / (increase) in prepaid expenses and other current assets		(20.1	)		36.2
Increase / (decrease) in accounts payable and accrued expenses		(1,242.9	)		(199.8	)
Increase / (decrease) in income and other net taxes payable		2.1			60.0
Increase / (decrease) in other assets and liabilities		(20.5	)		(52.7	)
Net cash provided by operating activities		116.5			1,234.0
Cash Flows From Investing Activities:
Additions to property, plant and equipment		(60.4	)		(64.8	)
Additions to product rights and other intangibles		(57.6	)		(7.5	)
Additions to investments		(5.0	)		(538.2	)
Proceeds from sale of investments and other assets		1,800.0			569.1
Proceeds from sales of property, plant and equipment		2.1			17.2
Acquisitions of businesses, net of cash acquired		-			(80.6	)
Net cash (used in) / provided by investing activities		1,679.1			(104.8	)
Cash Flows From Financing Activities:
Payments on debt, including finance lease obligations and credit facility		(3,031.8	)		(159.4	)
Payments of contingent consideration and other financing		(2.8	)		(2.0	)
Proceeds from stock plans		64.4			9.7
Repurchase of ordinary shares		(54.7	)		(829.2	)
Dividends paid		(243.5	)		(246.1	)
Net cash (used in) financing activities		(3,268.4	)		(1,227.0	)
Effect of currency exchange rate changes on cash and cash equivalents		(31.0	)		5.9
Net increase / (decrease) in cash and cash equivalents		(1,503.8	)		(91.9	)
Cash and cash equivalents at beginning of period		2,503.3			880.4
Cash and cash equivalents at end of period	$	999.5		$	788.5
Supplemental Disclosures of Cash Flow Information
Cash paid during the year for:
Income taxes other, net of refunds	$	68.7		$	105.4
Interest	$	237.6		$	252.0
Schedule of Non-Cash Investing and Financing Activities:
Dividends accrued	$	244.5		$	1.4

See accompanying Notes to the Consolidated Financial Statements.

ALLERGAN PLC

CONSOLIDATED STATEMENTS OF EQUITY

(Unaudited; in millions)

												Accumulated
						Additional						Other
	Ordinary Shares					Paid-in-			Retained			Comprehensive			Noncontrolling
	Shares			Amount		Capital			Earnings			Income / (Loss)			Interest		Total
BALANCE, December 31, 2018		332.6		$	-	$	56,510.0		$	7,258.9		$	1,345.2		$	16.9	$	65,131.0
Implementation of new accounting pronouncement		-			-		-			(22.0	)		-			-		(22.0	)
BALANCE, January 1, 2019		332.6		$	-	$	56,510.0		$	7,236.9		$	1,345.2		$	16.9	$	65,109.0
Comprehensive (loss):
Net (loss) attributable to shareholders		-			-		-			(2,408.0	)		-			-		(2,408.0	)
Other comprehensive (loss), net of tax		-			-		-			-			(128.8	)		-		(128.8	)
Share-based compensation		-			-		52.3			-			-			-		52.3
Ordinary shares issued under employee stock plans		0.7			-		9.7			-			-			-		9.7
Dividends declared		-			-		-			(246.1	)		-			-		(246.1	)
Repurchase of ordinary shares under the share repurchase programs		(5.3	)		-		(799.7	)		-			-			-		(799.7	)
Repurchase of ordinary shares		(0.2	)		-		(29.5	)		-			-			-		(29.5	)
Movement in noncontrolling interest		-			-		-			-			-			0.7		0.7
BALANCE, March 31, 2019		327.8		$	-	$	55,742.8		$	4,582.8		$	1,216.4		$	17.6	$	61,559.6

BALANCE, December 31, 2019		328.6		$	-	$	55,974.9		$	991.5		$	1,207.2		$	22.8	$	58,196.4
Comprehensive income:
Net income attributable to shareholders		-			-		-			378.0			-			-		378.0
Other comprehensive income, net of tax		-			-		-			-			(128.2	)		-		(128.2	)
Share-based compensation		-			-		51.6			-			-			-		51.6
Ordinary shares issued under employee stock plans		1.4			-		64.4			-			-			-		64.4
Dividends declared		-			-		-			(487.0	)		-			-		(487.0	)
Repurchase of ordinary shares		(0.3	)		-		(54.7	)		-			-			-		(54.7	)
Movement in noncontrolling interest		-			-		-			-			-			1.0		1.0
BALANCE, March 31, 2020		329.7			-		56,036.2			882.5			1,079.0			23.8		58,021.5

See accompanying Notes to the Consolidated Financial Statements.

WARNER CHILCOTT LIMITED

CONSOLIDATED BALANCE SHEETS

(Unaudited; in millions)

	March 31,			December 31,
	2020			2019
ASSETS
Current assets:
Cash and cash equivalents	$	990.5		$	2,497.1
Marketable securities		1,618.8			3,411.6
Accounts receivable, net of allowances for doubtful accounts and credit losses of $144.8 and $110.8		2,800.6			3,192.3
Receivables from Parents		539.0			409.3
Inventories		1,199.9			1,133.1
Prepaid expenses and other current assets		855.3			886.4
Total current assets		8,004.1			11,529.8
Property, plant and equipment, net		1,915.4			1,926.5
Right of use asset - operating leases		481.0			490.4
Investments and other assets		430.7			408.0
Non current assets held for sale		31.7			31.7
Deferred tax assets		597.9			576.9
Product rights and other intangibles		36,266.2			37,890.6
Goodwill		41,229.2			42,248.3
Total assets	$	88,956.2		$	95,102.2
LIABILITIES AND EQUITY
Current liabilities:
Accounts payable and accrued expenses	$	5,044.9		$	6,347.0
Payables to Parents		2,899.9			2,715.5
Income taxes payable		73.5			65.1
Current portion of long-term debt		1,950.7			4,532.5
Current portion of lease liability - operating		119.8			124.4
Total current liabilities		10,088.8			13,784.5
Long-term debt		17,599.0			18,116.5
Lease liability - operating		438.3			446.1
Other long-term liabilities		787.9			801.4
Other taxes payable		1,683.9			1,698.6
Deferred tax liabilities		2,455.8			4,363.2
Total liabilities		33,053.7			39,210.3
Commitments and contingencies (Refer to Note 15)
Equity:
Members' capital		63,780.1			64,023.6
(Accumulated deficit)		(8,980.4	)		(9,361.7	)
Accumulated other comprehensive income		1,079.0			1,207.2
Total members’ equity		55,878.7			55,869.1
Noncontrolling interest		23.8			22.8
Total equity		55,902.5			55,891.9
Total liabilities and equity	$	88,956.2		$	95,102.2

See accompanying Notes to the Consolidated Financial Statements.

WARNER CHILCOTT LIMITED

CONSOLIDATED STATEMENTS OF OPERATIONS

(Unaudited; in millions)

	Three Months Ended March 31,
	2020			2019
Net revenues	$	3,604.4		$	3,597.1
Operating expenses:
Cost of sales (excludes amortization and impairment of acquired intangibles including product rights)		623.1			497.8
Research and development		430.0			435.0
Selling and marketing		972.1			804.0
General and administrative		398.0			306.1
Amortization		1,416.4			1,399.4
Goodwill impairments		913.0			2,467.0
Asset sales and impairments, net		148.1			(5.2	)
Total operating expenses		4,900.7			5,904.1
Operating (loss) / income		(1,296.3	)		(2,307.0	)

Interest income		21.2			21.3
Interest (expense)		(184.5	)		(201.8	)
Other (expense) income, net		(24.9	)		13.8
Total other (expense), net		(188.2	)		(166.7	)
(Loss) / income before income taxes and noncontrolling interest		(1,484.5	)		(2,473.7	)
(Benefit) for income taxes		(1,866.8	)		(68.7	)
Net income / (loss)		382.3			(2,405.0	)
(Income) attributable to noncontrolling interest		(1.0	)		(0.7	)
Net income / (loss) attributable to members	$	381.3		$	(2,405.7	)

See accompanying Notes to the Consolidated Financial Statements.

WARNER CHILCOTT LIMITED

CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME / (LOSS)

(Unaudited; in millions)

	Three Months Ended March 31,
	2020			2019
Net income / (loss)	$	382.3		$	(2,405.0	)
Other comprehensive (loss) / income
Foreign currency translation (losses)		(127.2	)		(127.8	)
Unrealized gains / (losses), net of tax		(1.0	)		(1.0	)
Total other comprehensive (loss), net of tax		(128.2	)		(128.8	)
Comprehensive income / (loss)		254.1			(2,533.8	)
Comprehensive (income) attributable to noncontrolling interest		(1.0	)		(0.7	)
Comprehensive income / (loss) attributable to members	$	253.1		$	(2,534.5	)

See accompanying Notes to the Consolidated Financial Statements.

WARNER CHILCOTT LIMITED

CONSOLIDATED STATEMENTS OF CASH FLOWS

(Unaudited; in millions)

	Three Months Ended March 31,
	2020			2019
Cash Flows From Operating Activities:
Net income / (loss)	$	382.3		$	(2,405.0	)
Reconciliation to net cash provided by operating activities:
Depreciation		56.8			47.5
Amortization		1,416.4			1,399.4
Provision for inventory reserve		28.4			18.8
Share-based compensation		51.6			52.3
Deferred income tax benefit		(1,931.1	)		(229.7	)
Goodwill impairments		913.0			2,467.0
(Gain) / loss on asset sales and impairments, net		148.1			(5.2	)
Non-cash extinguishment of debt		-			0.3
Amortization of deferred financing costs		4.1			4.6
Non-cash lease expense		35.9			30.1
Contingent consideration adjustments, including accretion		26.6			18.7
Other, net		65.2			(10.3	)
Changes in assets and liabilities (net of effects of acquisitions):
Decrease / (increase) in accounts receivable, net		330.2			132.4
Decrease / (increase) in inventories		(126.3	)		(128.3	)
Decrease / (increase) in prepaid expenses and other current assets		(20.1	)		40.4
Increase / (decrease) in accounts payable and accrued expenses		(1,000.0	)		(199.5	)
Increase / (decrease) in income and other net taxes payable		2.1			60.0
Increase / (decrease) in other assets and liabilities, including receivable / payable with Parents		(259.8	)		(79.3	)
Net cash provided by operating activities		123.4			1,214.2
Cash Flows From Investing Activities:
Additions to property, plant and equipment		(60.4	)		(64.8	)
Additions to product rights and other intangibles		(57.6	)		(7.5	)
Additions to investments		(5.0	)		(538.2	)
Proceeds from sale of investments and other assets		1,800.0			569.1
Proceeds from sales of property, plant and equipment		2.1			17.2
Acquisitions of businesses, net of cash acquired		-			(80.6	)
Net cash (used in) / provided by investing activities		1,679.1			(104.8	)
Cash Flows From Financing Activities:
Payments on debt, including finance lease obligations and credit facility		(3,031.8	)		(159.4	)
Payments of contingent consideration and other financing		(2.8	)		(2.0	)
Dividends to Parents		(243.5	)		(1,045.8	)
Net cash (used in) financing activities		(3,278.1	)		(1,207.2	)
Effect of currency exchange rate changes on cash and cash equivalents		(31.0	)		5.9
Net increase / (decrease) in cash and cash equivalents		(1,506.6	)		(91.9	)
Cash and cash equivalents at beginning of period		2,497.1			878.6
Cash and cash equivalents at end of period	$	990.5		$	786.7

See accompanying Notes to the Consolidated Financial Statements.

WARNER CHILCOTT LIMITED

CONSOLIDATED STATEMENTS OF EQUITY

(Unaudited; in millions, except share data)

	Members' Capital
	Shares		Amount			(Accumulated Deficit)			Accumulated Other Comprehensive Income / (Loss)			Noncontrolling Interest		Total
BALANCE, December 31, 2018		100.0	$	65,797.9		$	(4,219.7	)	$	1,345.2		$	16.9	$	62,940.3
Implementation of new accounting pronouncements		-		-			(22.0	)		-			-		(22.0	)
BALANCE, January 1, 2019		100.0	$	65,797.9		$	(4,241.7	)	$	1,345.2		$	16.9	$	62,918.3
Comprehensive (loss):
Net (loss) attributable to members		-		-			(2,405.7	)		-			-		(2,405.7	)
Other comprehensive (loss), net of tax		-		-			-			(128.8	)		-		(128.8	)
Dividends to Parents		-		(1,045.8	)		-			-			-		(1,045.8	)
Movement in noncontrolling interest		-		-			-			-			0.7		0.7
BALANCE, March 31, 2019		100.0	$	64,752.1		$	(6,647.4	)	$	1,216.4		$	17.6	$	59,338.7

Allergan plc 10-Q